Scarica l'app Stockscreener
26.04
1.36%
0.35
Pre-mercato:
25.98
-0.06
-0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
US FDA approves Pfizer's bleeding disorder drug for children - Reuters
FDA approves first weekly hemophilia B shot for kids 6-11 - Stock Titan
Barclays Maintains Pfizer(PFE.US) With Sell Rating, Maintains Target Price $25 - Moomoo
Pfizer-Partnered Obesity Drugmaker Eyes Deals Outside China - Bloomberg.com
Pfizer (PFE) Stock Gains Ground on Once-Monthly Obesity Drug Breakthrough - Blockonomi
3 Dividend Stocks to Buy Hand Over Fist in June - The Motley Fool
Pfizer’s monthly obesity shot has side-effect profile similar to Wegovy - NewsNation
Pfizer working on 1st once-a-month anti-obesity drug - Magzter
What to know about berobenatide, Pfizer’s experimental obesity drug - AOL.com
Pfizer’s Berobenatide GLP-1 Obesity Data Might Change The Case For Investing In Pfizer (PFE) - Yahoo Finance
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer. - The Motley Fool
Pfizer Revenue Recovery and Patent Cliff: Analysis as of June 2026News and Statistics - IndexBox
Comirnaty COVID-19 vaccine: what US patients should know - AD HOC NEWS
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems - AOL.com
Pfizer (PFE) Advances Obesity Therapy with Promising Mid-Stage T - GuruFocus
Pfizer says mid-stage trial data support monthly dosing for GLP-1 therapy - Seeking Alpha
Pfizer targets obesity market with monthly weight-loss injection data - Investing.com
Pfizer Bets on Weight-Loss Drugs to Power Its Next Decade - Bloomberg.com
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide - The Joplin Globe
Assessing Pfizer (PFE) Valuation As Shares Recover From A Mixed Recent Performance - Yahoo Finance
Pfizer Options Spot-On: On June 5th, 143.52K Contracts Were Traded, With 2.67 Million Open Interest - Moomoo
Pfizer Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Pfizer Inc. stock (US7170811035): shares steady ahead of next catalyst as investors focus on valuati - AD HOC NEWS
Pfizer’s integrin β6 ADC advances intravesical therapy for NMIBC - BioWorld News
Pfizer licenses Chai Discovery AI platform for drug discovery - Yahoo Finance
PFIZER INC : Jefferies reaffirms its Buy rating - marketscreener.com
Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit and more - Medical Marketing and Media
Pfizer signs licence agreement with Chai for AI drug discovery - Yahoo Finance
PFE.DE Technical Analysis | Trend, Signals & Chart Patterns | PFIZER INC (FRA:PFE) - ChartMill
How New Multi‑Tumor Oncology Data At Pfizer (PFE) Has Changed Its Investment Story - simplywall.st
Pfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord Pharma
Diamond Blackfan Anemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Novartis AG, AstraZeneca, Pfizer Inc., Sanofi, Merck KGaA - Barchart.com
Pfizer Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Pfizer Taps Chai Discovery AI To Expand Biologics Pipeline Potential - Yahoo Finance
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI - The National Law Review
Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report? - Yahoo Finance
Pfizer Inc stock (US7170811035): focus on oncology pipeline after Jefferies 2026 appearance - AD HOC NEWS
Pfizer to Leverage Chai Discovery’s AI Platform - Contract Pharma
Pfizer Inc. stock (US7170811035): oncology collaboration focus after Jefferies conference update - AD HOC NEWS
Southwest Securities: Innovent Bio (01801) Partners with Pfizer to Accelerate Development of Innovative Oncology Therapies - 富途牛牛
Innovent’s $10.5 billion deal marks new model for China drugmakers - thebambooworks.com
Pfizer Inc. stock (US7170811035): shares steady as investors digest oncology deal news and recent ea - AD HOC NEWS
Pfizer vs Merck: Chasing High Yield vs Higher Returns - 24/7 Wall St.
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? - The Globe and Mail
Meet the biotech stock that's trouncing Lilly, Merck, and Pfizer in 2026 - MSN
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 - Yahoo Finance
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story - Yahoo Finance
Pfizer lifts 2022 forecast for Covid-19 vaccine sales as profits rise - Digital Journal
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal - BioWorld News
Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership? - Insider Monkey
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026 - The Globe and Mail
Why Pfizer’s Current Price May Be Too Cheap to Ignore - Yahoo Finance
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock - Yahoo Finance Singapore
Pfizer’s ASCO 2026 Cancer Results Test Oncology Focus And Valuation Story - simplywall.st
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
Pfizer Inc (PFE) CEO receives grant of 23 phantom stock units - Stock Titan
0.02%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):